Phaseline

Targets › ESR2

ESR2 (Estrogen receptor beta): drug programs, companies and trials

29 programs from 28 companies in 35 trials: 16 Phase 2, 9 Phase 4, 7 Phase 3, 3 Phase 1; Oncology, Genitourinary, Psychiatry; next expected readout Dec 2026.

Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner..; FUNCTION: [Isoform 2]: Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability. (UniProt, Q92731)

Open in Phaseline: the race on ESR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoHormone Replacement Therapy (HRT)
Estrogen and progestin replacement
ESR1, ESR2, PGRPhase 4Adhesive Capsulitis of the ShoulderDec 2026
The AlfredBazedoxifene Acetate
Selective estrogen receptor modulator (SERM)
ESR1, ESR2Phase 4SchizophreniaDec 2026
Mackay Memorial HospitalConjugated equine estrogen (Premarin)
Estrogen receptor agonist (vaginal cream formulation)
ESR1, ESR2Phase 4Effect of DrugDec 2026
Insel Gruppe AG, University Hospital BernHormone Replacement Therapy (HRT)
Transdermal estradiol and oral micronized progesterone replacement
ESR1, ESR2, PGRPhase 4InsomniaJan 2027
University of California, IrvineEstring Vaginal Product
Estradiol released locally from a vaginal ring
ESR1, ESR2Phase 4Recurrent Urinary Tract InfectionJun 2027
Andrew ZakhariEstetrol
Estrogen receptor agonist
ESR2, ESR1Phase 4Ovarian EndometriomaJul 2027
Penn State UniversityCombined Oral Contraceptive (COC) / Apri (Reclipsen)
Oral ethinyl estradiol-based contraceptive; estrogen receptor agonist
ESR1, ESR2, PGRPhase 4Other Disorders of Bone Development and GrowthDec 2028
LeonaBioLasofoxifene
Estrogen receptor modulator
ESR2, ESR1Phase 3Metastatic Breast CancerApr 2027
Wen TianfuChlorotrianisene
Estrogen receptor beta modulator
ESR2Phase 3Advanced Hepatocellular CarcinomaMay 2027
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sChlorotrianisene
Estrogen receptor beta modulator
ESR2Phase 3Hepatocellular CarcinomaJun 2027
Sarah WozneyConjugated Estrogens CSD
Estrogen receptor agonist
ESR1, ESR2Phase 3Pelvic Organ Prolapse (POP)Sep 2027
Assistance Publique - Hôpitaux de ParisEstrogens (ESTREVA® 0.1% gel or PROVAMES® 1 mg)
Estrogen receptor agonist
ESR1, ESR2Phase 3Gender DysphoriaJun 2029
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Estrogens, Conjugated
Estrogen receptor agonist
ESR2, ESR1Phase 3Premature Ovarian InsufficiencyDec 2031
Hatice Tukenmez KurnazEstriol
Estrogen receptor modulator
ESR2, ESR1Phase 3Pelvic Organ Prolapse–
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairRaloxifene
Estrogen receptor beta modulator; Estrogen receptor modulator
ESR2, ESR1Phase 2Breast Cancer; BPH (Benign Prostatic Hyperplasia); Brain TumorDec 2026
Tianjin Medical University Cancer Institute and HospitalToremifene
Estrogen receptor modulator
ESR2, ESR1Phase 2CANCERDec 2026
Azure BiotechLasofoxifene Tartrate (AZU-101)
Estrogen receptor modulator
ESR2, ESR1Phase 2Vulvo Vaginal Atrophy (VVA)Dec 2026
University of Southern Californiabazedoxifene / conjugated estrogens
Tissue selective estrogen complex (TSEC)
ESR1, ESR2Phase 2AtherosclerosisDec 2026
Roberta BrintonPhytoSERM
Phytoestrogen supplement containing genistein, daidzein, and S-equol
ESR1, ESR2Phase 2MenopauseJan 2027
UNC Lineberger Comprehensive Cancer Centertoremifene
Estrogen receptor modulator
ESR2, ESR1Phase 2Breast CancerApr 2027
University of Kansas Medical CenterBazedoxifene and Conjugated Estrogens
Selective estrogen receptor modulator (SERM) plus estrogen hormone replacement therapy
ESR1, ESR2Phase 2Risk ReductionJul 2027
Nutrindo Ideais Research CenterOESTROGEL
Transdermal estradiol; estrogen receptor agonist
ESR1, ESR2Phase 2MenopauseOct 2027
Nutrindo Ideais Research CenterPENTRAVAN
Transdermal estradiol delivery system; estrogen receptor agonist
ESR1, ESR2Phase 2MenopauseOct 2027
Fred Hutchinson Cancer CenterTransdermal Estrogen
Estrogen receptor agonist
ESR1, ESR2Phase 2Castration-Sensitive Prostate AdenocarcinomaJun 2029
University of Virginiatransdermal 17β-E2 with cyclic progestin
Estrogen receptor agonist with cyclic progestin
ESR1, ESR2, PGRPhase 2Bone StrengthDec 2029
Northwestern UniversityAfimoxifene
Estrogen receptor modulator; Estrogen-related receptor gamma antagonist
ESR2, ESR1, ESRRGPhase 2Cancer Survivor–
University of PennsylvaniaEstrogens, Conjugated
Estrogen receptor agonist
ESR2, ESR1Phase 1Ischemia Reperfusion InjuryJan 2027
St. Joseph's Healthcare HamiltonDuavive (conjugated estrogens/bazedoxifene)
Estrogen receptor agonist with selective estrogen receptor modulator component
ESR1, ESR2Phase 1Menopause–
University of OxfordMenopausal hormone therapy (systemic, oestrogen-containing)
Oestrogen receptor agonist
ESR1, ESR2Phase 1Menopause–

Conditions

Menopause (5) Bone Strength (3) Breast Cancer (2) Recurrent Urinary Tract Infection (2) Other Disorders of Bone Development and Growth (2) Pelvic Organ Prolapse (POP) (1) Hepatocellular Carcinoma (1) BPH (Benign Prostatic Hyperplasia) (1) Brain Tumor (1) Risk Reduction (1) Premature Ovarian Insufficiency (1) Pelvic Organ Prolapse (1)

Modalities

small molecule (24), antibody (1), mixed (1)

Companies

Nutrindo Ideais Research Center (2) Sarah Wozney (1) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) University of Kansas Medical Center (1) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) St. Joseph's Healthcare Hamilton (1) Hatice Tukenmez Kurnaz (1) Wen Tianfu (1) Andrew Zakhari (1) The Alfred (1) Northwestern University (1) Mackay Memorial Hospital (1) University of Oxford (1) University of California, San Francisco (1) University of Virginia (1) University of California, Irvine (1) Roberta Brinton (1) Fred Hutchinson Cancer Center (1) University of Pennsylvania (1)

Related targets

ESR1 (27) PGR (4) ESRRG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.